FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110534467> ?p ?o ?g. }

• W2110534467 endingPage "298" @default.
• W2110534467 startingPage "292" @default.
• W2110534467 abstract "TAC (docetaxel/doxorubicin/cyclophosphamide) is associated with high incidences of grade 4 neutropenia and febrile neutropenia (FN). This analysis compared the efficacies of four regimens for primary prophylaxis of FN and related toxic effects in breast cancer patients receiving neoadjuvant TAC.Patients with stage T2-T4 primary breast cancer were scheduled to receive 6-8 cycles of TAC. Primary prophylaxis was: ciprofloxacin 500 mg orally twice daily on days 5-14 (n = 253 patients; 1478 cycles), daily granulocyte colony-stimulating factor (G-CSF) (filgrastim 5 microg/kg/day or lenograstim 150 microg/m(2)/day) on days 5-10 (n = 377; 2400 cycles), pegfilgrastim 6 mg on day 2 (n = 305; 1930 cycles), or pegfilgrastim plus ciprofloxacin (n = 321; 1890 cycles).Pegfilgrastim with/without ciprofloxacin was significantly more effective than daily G-CSF or ciprofloxacin in preventing FN (5% and 7% versus 18% and 22% of patients; all P < 0.001), grade 4 neutropenia, and leukopenia. Pegfilgrastim plus ciprofloxacin completely prevented first cycle FN (P < 0.01 versus pegfilgrastim alone) and fatal neutropenic events.Ciprofloxacin alone, or daily G-CSF from day 5-10 (as in common practice), provided suboptimal protection against FN and related toxic effects in patients receiving TAC. Pegfilgrastim was significantly more effective in this setting, especially if given with ciprofloxacin." @default.
• W2110534467 created "2016-06-24" @default.
• W2110534467 creator A5002412211 @default.
• W2110534467 creator A5004942036 @default.
• W2110534467 creator A5011410319 @default.
• W2110534467 creator A5014934109 @default.
• W2110534467 creator A5016987068 @default.
• W2110534467 creator A5035387502 @default.
• W2110534467 creator A5047695952 @default.
• W2110534467 creator A5056688392 @default.
• W2110534467 creator A5067146231 @default.
• W2110534467 creator A5067473376 @default.
• W2110534467 creator A5069170386 @default.
• W2110534467 creator A5070416057 @default.
• W2110534467 creator A5071658752 @default.
• W2110534467 creator A5076180960 @default.
• W2110534467 creator A5080450879 @default.
• W2110534467 creator A5087559224 @default.
• W2110534467 date "2008-02-01" @default.
• W2110534467 modified "2023-10-13" @default.
• W2110534467 title "Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study" @default.
• W2110534467 cites W1964094292 @default.
• W2110534467 cites W1970800877 @default.
• W2110534467 cites W2014576677 @default.
• W2110534467 cites W2036450045 @default.
• W2110534467 cites W2075213874 @default.
• W2110534467 cites W2088580367 @default.
• W2110534467 cites W2096288062 @default.
• W2110534467 cites W2096334407 @default.
• W2110534467 cites W2100082529 @default.
• W2110534467 cites W2109079833 @default.
• W2110534467 cites W2122658272 @default.
• W2110534467 cites W2140654333 @default.
• W2110534467 cites W2142195688 @default.
• W2110534467 cites W2164788594 @default.
• W2110534467 cites W2166858780 @default.
• W2110534467 cites W2169203358 @default.
• W2110534467 cites W2226490553 @default.
• W2110534467 cites W2590956405 @default.
• W2110534467 cites W45925396 @default.
• W2110534467 doi "https://doi.org/10.1093/annonc/mdm438" @default.
• W2110534467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17846019" @default.
• W2110534467 hasPublicationYear "2008" @default.
• W2110534467 type Work @default.
• W2110534467 sameAs 2110534467 @default.
• W2110534467 citedByCount "128" @default.
• W2110534467 countsByYear W21105344672012 @default.
• W2110534467 countsByYear W21105344672013 @default.
• W2110534467 countsByYear W21105344672014 @default.
• W2110534467 countsByYear W21105344672015 @default.
• W2110534467 countsByYear W21105344672016 @default.
• W2110534467 countsByYear W21105344672017 @default.
• W2110534467 countsByYear W21105344672018 @default.
• W2110534467 countsByYear W21105344672019 @default.
• W2110534467 countsByYear W21105344672020 @default.
• W2110534467 countsByYear W21105344672021 @default.
• W2110534467 countsByYear W21105344672022 @default.
• W2110534467 countsByYear W21105344672023 @default.
• W2110534467 crossrefType "journal-article" @default.
• W2110534467 hasAuthorship W2110534467A5002412211 @default.
• W2110534467 hasAuthorship W2110534467A5004942036 @default.
• W2110534467 hasAuthorship W2110534467A5011410319 @default.
• W2110534467 hasAuthorship W2110534467A5014934109 @default.
• W2110534467 hasAuthorship W2110534467A5016987068 @default.
• W2110534467 hasAuthorship W2110534467A5035387502 @default.
• W2110534467 hasAuthorship W2110534467A5047695952 @default.
• W2110534467 hasAuthorship W2110534467A5056688392 @default.
• W2110534467 hasAuthorship W2110534467A5067146231 @default.
• W2110534467 hasAuthorship W2110534467A5067473376 @default.
• W2110534467 hasAuthorship W2110534467A5069170386 @default.
• W2110534467 hasAuthorship W2110534467A5070416057 @default.
• W2110534467 hasAuthorship W2110534467A5071658752 @default.
• W2110534467 hasAuthorship W2110534467A5076180960 @default.
• W2110534467 hasAuthorship W2110534467A5080450879 @default.
• W2110534467 hasAuthorship W2110534467A5087559224 @default.
• W2110534467 hasBestOaLocation W21105344671 @default.
• W2110534467 hasConcept C121608353 @default.
• W2110534467 hasConcept C126322002 @default.
• W2110534467 hasConcept C141071460 @default.
• W2110534467 hasConcept C143998085 @default.
• W2110534467 hasConcept C2776694085 @default.
• W2110534467 hasConcept C2776755627 @default.
• W2110534467 hasConcept C2777063308 @default.
• W2110534467 hasConcept C2778658803 @default.
• W2110534467 hasConcept C2778850193 @default.
• W2110534467 hasConcept C2779171977 @default.
• W2110534467 hasConcept C2780873365 @default.
• W2110534467 hasConcept C2781190966 @default.
• W2110534467 hasConcept C530470458 @default.
• W2110534467 hasConcept C71924100 @default.
• W2110534467 hasConcept C90924648 @default.
• W2110534467 hasConceptScore W2110534467C121608353 @default.
• W2110534467 hasConceptScore W2110534467C126322002 @default.
• W2110534467 hasConceptScore W2110534467C141071460 @default.
• W2110534467 hasConceptScore W2110534467C143998085 @default.
• W2110534467 hasConceptScore W2110534467C2776694085 @default.
• W2110534467 hasConceptScore W2110534467C2776755627 @default.
• W2110534467 hasConceptScore W2110534467C2777063308 @default.

• next